BBIO vs. OGN, APLS, MDGL, IONS, NUVL, ALPN, PRGO, ALKS, INSM, and BPMC Should you be buying BridgeBio Pharma stock or one of its competitors? The main competitors of BridgeBio Pharma include Organon & Co. (OGN), Apellis Pharmaceuticals (APLS), Madrigal Pharmaceuticals (MDGL), Ionis Pharmaceuticals (IONS), Nuvalent (NUVL), Alpine Immune Sciences (ALPN), Perrigo (PRGO), Alkermes (ALKS), Insmed (INSM), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical preparations" industry.
BridgeBio Pharma (NASDAQ:BBIO ) and Organon & Co. (NYSE:OGN ) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, community ranking, dividends, earnings, analyst recommendations, valuation and risk.
BridgeBio Pharma received 124 more outperform votes than Organon & Co. when rated by MarketBeat users. Likewise, 67.63% of users gave BridgeBio Pharma an outperform vote while only 33.33% of users gave Organon & Co. an outperform vote.
BridgeBio Pharma currently has a consensus price target of $48.00, indicating a potential upside of 59.52%. Organon & Co. has a consensus price target of $22.60, indicating a potential upside of 3.67%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, research analysts plainly believe BridgeBio Pharma is more favorable than Organon & Co..
In the previous week, BridgeBio Pharma had 9 more articles in the media than Organon & Co.. MarketBeat recorded 16 mentions for BridgeBio Pharma and 7 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.95 beat BridgeBio Pharma's score of 0.61 indicating that Organon & Co. is being referred to more favorably in the news media.
BridgeBio Pharma has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500. Comparatively, Organon & Co. has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500.
99.9% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 77.4% of Organon & Co. shares are held by institutional investors. 28.5% of BridgeBio Pharma shares are held by company insiders. Comparatively, 1.2% of Organon & Co. shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Organon & Co. has a net margin of 16.50% compared to BridgeBio Pharma's net margin of -246.24%. BridgeBio Pharma's return on equity of 0.00% beat Organon & Co.'s return on equity.
Organon & Co. has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.
Summary BridgeBio Pharma beats Organon & Co. on 12 of the 19 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding BBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
BridgeBio Pharma Competitors List
Related Companies and Tools
